News Releases

Date Title  
Toggle Summary Adamis Pharmaceuticals Announces Results of Annual Meeting of Stockholders
Meeting adjourned only with respect to reverse stock split proposal until September 8, 2022 SAN DIEGO , Aug. 12, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that its 2022 Annual Meeting of Stockholders (“Annual Meeting”) was convened, as scheduled.
Adamis Pharmaceuticals Announces Results of Annual Meeting of Stockholders
Meeting adjourned only with respect to reverse stock split proposal until September 8, 2022 SAN DIEGO , Aug. 12, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that its 2022 Annual Meeting of Stockholders (“Annual Meeting”) was convened, as scheduled.
Toggle Summary Adamis Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Management to host webcast/conference call today at 1:30 p.m. PT / 4:30 p.m. ET SAN DIEGO , Aug. 10, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation  (NASDAQ: ADMP), a commercial-stage biopharmaceutical company primarily focused on developing and commercializing products in various
Adamis Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Management to host webcast/conference call today at 1:30 p.m. PT / 4:30 p.m. ET SAN DIEGO , Aug. 10, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation  (NASDAQ: ADMP), a commercial-stage biopharmaceutical company primarily focused on developing and commercializing products in various
Toggle Summary Adamis Pharmaceuticals Schedules Second Quarter 2022 Financial Results Conference Call and Corporate Update
SAN DIEGO , Aug. 08, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory disease, today announced that it will host an investor conference
Adamis Pharmaceuticals Schedules Second Quarter 2022 Financial Results Conference Call and Corporate Update
SAN DIEGO , Aug. 08, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory disease, today announced that it will host an investor conference
Toggle Summary Leading Independent Proxy Advisory Firm ISS Recommends Adamis Pharmaceuticals’ Stockholders Vote FOR Critical Proposals at Upcoming Annual Meeting
ISS Recommends Stockholders Support Key Proposals  Pertaining to a Reverse Stock Split and New Equity Incentive Plan The Deadline for Stockholders to Vote (or Change Their Vote) is 11:59 p.m. PT on August 11, 2022 SAN DIEGO , July 29, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation
Leading Independent Proxy Advisory Firm ISS Recommends Adamis Pharmaceuticals’ Stockholders Vote FOR Critical Proposals at Upcoming Annual Meeting
ISS Recommends Stockholders Support Key Proposals  Pertaining to a Reverse Stock Split and New Equity Incentive Plan The Deadline for Stockholders to Vote (or Change Their Vote) is 11:59 p.m. PT on August 11, 2022 SAN DIEGO , July 29, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation
Toggle Summary Adamis Pharmaceuticals Provides Update on Clinical Study Assessing Tempol for the Treatment of COVID-19
Interim DSMB review expected in late September SAN DIEGO , July 29, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today provided an update on the Company’s ongoing U.S. Phase 2/3 clinical trial to evaluate the safety and efficacy of Tempol as a treatment for COVID-19.
Adamis Pharmaceuticals Provides Update on Clinical Study Assessing Tempol for the Treatment of COVID-19
Interim DSMB review expected in late September SAN DIEGO , July 29, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today provided an update on the Company’s ongoing U.S. Phase 2/3 clinical trial to evaluate the safety and efficacy of Tempol as a treatment for COVID-19.
Toggle Summary Adamis Pharmaceuticals Issues Letter to Stockholders
SAN DIEGO , July 21, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory diseases, issued the following letter to stockholders from Chief
Adamis Pharmaceuticals Issues Letter to Stockholders
SAN DIEGO , July 21, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory diseases, issued the following letter to stockholders from Chief
Toggle Summary Adamis Pharmaceuticals Provides Update on Clinical Study Assessing Tempol for the Treatment of COVID-19
DSMB Has Reviewed Interim Clinical and Safety Data and Recommended that the Study Continue SAN DIEGO , June 01, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose,
Adamis Pharmaceuticals Provides Update on Clinical Study Assessing Tempol for the Treatment of COVID-19
DSMB Has Reviewed Interim Clinical and Safety Data and Recommended that the Study Continue SAN DIEGO , June 01, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose,
Toggle Summary Adamis Appoints Vickie Reed to Board of Directors
New Director Named with Significant Executive Management and Financial Leadership Experience SAN DIEGO , May 26, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation  (Nasdaq: ADMP) today announced the appointment of Vickie Reed as a new director and member of the company’s board of
Adamis Appoints Vickie Reed to Board of Directors
New Director Named with Significant Executive Management and Financial Leadership Experience SAN DIEGO , May 26, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation  (Nasdaq: ADMP) today announced the appointment of Vickie Reed as a new director and member of the company’s board of
Toggle Summary Adamis Pharmaceuticals Announces Leadership Transition to Support New Phase of Innovation and Growth
David J. Marguglio , Co-Founder and Chief Business Officer, Appointed President and CEO Dennis J. Carlo , Ph.D., Has Retired as Both CEO and Board Director SAN DIEGO , May 18, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and
Adamis Pharmaceuticals Announces Leadership Transition to Support New Phase of Innovation and Growth
David J. Marguglio , Co-Founder and Chief Business Officer, Appointed President and CEO Dennis J. Carlo , Ph.D., Has Retired as Both CEO and Board Director SAN DIEGO , May 18, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and
Toggle Summary Adamis Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
Management to host webcast/conference call today at 2 p.m. PT / 5 p.m. ET SAN DIEGO , May 16, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and
Adamis Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
Management to host webcast/conference call today at 2 p.m. PT / 5 p.m. ET SAN DIEGO , May 16, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and
Toggle Summary Adamis Pharmaceuticals Schedules First Quarter 2022 Financial Results Conference Call and Business Update
SAN DIEGO , May 09, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory disease, today announced that it will host an investor conference
Adamis Pharmaceuticals Schedules First Quarter 2022 Financial Results Conference Call and Business Update
SAN DIEGO , May 09, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory disease, today announced that it will host an investor conference
Toggle Summary Adamis Pharmaceuticals Reports Full Year 2021 Financial Results and Provides Corporate Update
Management to host webcast/conference call today at 2 p.m. PT / 5 p.m. ET SAN DIEGO , March 31, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and
Adamis Pharmaceuticals Reports Full Year 2021 Financial Results and Provides Corporate Update
Management to host webcast/conference call today at 2 p.m. PT / 5 p.m. ET SAN DIEGO , March 31, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and
Toggle Summary US WorldMeds and Adamis Pharmaceuticals Announce U.S. Launch of ZIMHI™ Naloxone Product
High-Dose Naloxone Now Available to Help Combat the Growing Epidemic of Overdose Deaths LOUISVILLE, Ky. and SAN DIEGO, March 31, 2022 (GLOBE NEWSWIRE) -- USWM, LLC ( US WorldMeds ), and Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), today announced the U.S.
US WorldMeds and Adamis Pharmaceuticals Announce U.S. Launch of ZIMHI™ Naloxone Product
High-Dose Naloxone Now Available to Help Combat the Growing Epidemic of Overdose Deaths LOUISVILLE, Ky. and SAN DIEGO, March 31, 2022 (GLOBE NEWSWIRE) -- USWM, LLC ( US WorldMeds ), and Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), today announced the U.S.
Toggle Summary Adamis Pharmaceuticals Schedules Fourth Quarter and Full Year 2021 Financial Results Conference Call and Business Update
SAN DIEGO , March 24, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory disease, today announced that it will host an investor
Adamis Pharmaceuticals Schedules Fourth Quarter and Full Year 2021 Financial Results Conference Call and Business Update
SAN DIEGO , March 24, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory disease, today announced that it will host an investor
Toggle Summary Adamis Pharmaceuticals Announces Results of Tempol in Omicron Virus Challenge in Hamster Model
Tempol Reduced Lung Inflammation After High Dose Challenge SAN DIEGO , March 22, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation  (Nasdaq: ADMP) today announced that in studies conducted at Galveston National Laboratory (GNL), University of Texas Medical Branch (UTMB) at Galveston,
Adamis Pharmaceuticals Announces Results of Tempol in Omicron Virus Challenge in Hamster Model
Tempol Reduced Lung Inflammation After High Dose Challenge SAN DIEGO , March 22, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation  (Nasdaq: ADMP) today announced that in studies conducted at Galveston National Laboratory (GNL), University of Texas Medical Branch (UTMB) at Galveston,
Toggle Summary Adamis Pharmaceuticals Corporation Issues Nationwide Voluntary Recall of SYMJEPI® (epinephrine) Injection for Potential Manufacturing Defect
SAN DIEGO , March 21, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation  (Nasdaq: ADMP) is voluntarily recalling certain lots of SYMJEPI (epinephrine) Injection 0.15 mg (0.15 mg/0.3 mL) and 0.3 mg (0.3 mg/0.3 mL) Pre-Filled Single-Dose Syringes to the consumer level.
Adamis Pharmaceuticals Corporation Issues Nationwide Voluntary Recall of SYMJEPI® (epinephrine) Injection for Potential Manufacturing Defect
SAN DIEGO , March 21, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation  (Nasdaq: ADMP) is voluntarily recalling certain lots of SYMJEPI (epinephrine) Injection 0.15 mg (0.15 mg/0.3 mL) and 0.3 mg (0.3 mg/0.3 mL) Pre-Filled Single-Dose Syringes to the consumer level.
Toggle Summary Adamis Pharmaceuticals Provides Update on Clinical Study Assessing Tempol for the Treatment of COVID-19
DSMB met to evaluate interim clinical and safety data and clears Phase 2/3 study to continue SAN DIEGO , March 14, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation  (Nasdaq: ADMP) today announced that on March 11, 2022 , the Data Safety Monitoring Board (DSMB) overseeing the Phase 2/3
Adamis Pharmaceuticals Provides Update on Clinical Study Assessing Tempol for the Treatment of COVID-19
DSMB met to evaluate interim clinical and safety data and clears Phase 2/3 study to continue SAN DIEGO , March 14, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation  (Nasdaq: ADMP) today announced that on March 11, 2022 , the Data Safety Monitoring Board (DSMB) overseeing the Phase 2/3
Toggle Summary Adamis Pharmaceuticals Announces Retirement of Richard C. Williams, Chairman of the Board
SAN DIEGO , March 04, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), today announced the retirement of Richard C. Williams , effective April 15, 2022 . “Dick has provided almost eight years of strategic leadership and committed service to Adamis and has provided
Adamis Pharmaceuticals Announces Retirement of Richard C. Williams, Chairman of the Board
SAN DIEGO , March 04, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), today announced the retirement of Richard C. Williams , effective April 15, 2022 . “Dick has provided almost eight years of strategic leadership and committed service to Adamis and has provided
Toggle Summary Adamis Pharmaceuticals’ Clinical Study Assessing Tempol for the Treatment of COVID-19 Surpasses Enrollment Expectations
Ad-hoc DSMB meeting evaluates interim clinical and safety data and clears Phase 2/3 study to continue SAN DIEGO , Feb. 28, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation  (Nasdaq: ADMP) today announced that due to the acceleration of patient enrollment in the double-blind placebo
Adamis Pharmaceuticals’ Clinical Study Assessing Tempol for the Treatment of COVID-19 Surpasses Enrollment Expectations
Ad-hoc DSMB meeting evaluates interim clinical and safety data and clears Phase 2/3 study to continue SAN DIEGO , Feb. 28, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation  (Nasdaq: ADMP) today announced that due to the acceleration of patient enrollment in the double-blind placebo
Toggle Summary Adamis Announces Inducement Option Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO , Feb. 18, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease,
Adamis Announces Inducement Option Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO , Feb. 18, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease,
Toggle Summary Adamis Pharmaceuticals Provides Enrollment Update of Subjects in Phase 2/3 Study of Tempol for the Treatment of COVID-19
SAN DIEGO , Feb. 07, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation  (Nasdaq: ADMP) today announced the enrollment and dosing of more than 100 subjects in the Company’s ongoing Phase 2/3 study of Tempol for the treatment of COVID-19. The Data Safety Monitoring Board (DSMB) will now
Adamis Pharmaceuticals Provides Enrollment Update of Subjects in Phase 2/3 Study of Tempol for the Treatment of COVID-19
SAN DIEGO , Feb. 07, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation  (Nasdaq: ADMP) today announced the enrollment and dosing of more than 100 subjects in the Company’s ongoing Phase 2/3 study of Tempol for the treatment of COVID-19. The Data Safety Monitoring Board (DSMB) will now
Toggle Summary Adamis Pharmaceuticals Submits Fast Track Application to FDA for Tempol for the Treatment and Prevention of COVID-19
SAN DIEGO , Jan. 10, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation  (Nasdaq: ADMP) today announced the submission of a Fast Track Application to the U.S. Food and Drug Administration (FDA) for Tempol for the treatment and prevention of COVID-19.
Adamis Pharmaceuticals Submits Fast Track Application to FDA for Tempol for the Treatment and Prevention of COVID-19
SAN DIEGO , Jan. 10, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation  (Nasdaq: ADMP) today announced the submission of a Fast Track Application to the U.S. Food and Drug Administration (FDA) for Tempol for the treatment and prevention of COVID-19.
Toggle Summary Adamis Pharmaceuticals Updates Comparative Pharmacology Model Data Supporting the Higher 5 mg Intramuscular Dose of Naloxone in ZIMHI™
Drug overdoses are the leading cause of death for those under age 50 SAN DIEGO , Dec. 01, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced today that additional data in a quantitative systems pharmacology model supports the dose of naloxone hydrochloride that is
Adamis Pharmaceuticals Updates Comparative Pharmacology Model Data Supporting the Higher 5 mg Intramuscular Dose of Naloxone in ZIMHI™
Drug overdoses are the leading cause of death for those under age 50 SAN DIEGO , Dec. 01, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced today that additional data in a quantitative systems pharmacology model supports the dose of naloxone hydrochloride that is
Toggle Summary Adamis Pharmaceuticals Regains Compliance with NASDAQ Continued Listing Requirements
SAN DIEGO , Nov. 23, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory disease, today announced that it has received a letter from the
Adamis Pharmaceuticals Regains Compliance with NASDAQ Continued Listing Requirements
SAN DIEGO , Nov. 23, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory disease, today announced that it has received a letter from the
Toggle Summary Adamis Pharmaceuticals Announces Third Quarter 2021 Financial Results and Provides Corporate Update
Management to host webcast/conference call today at 2 p.m. PT / 5 p.m. ET SAN DIEGO , Nov. 22, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and
Adamis Pharmaceuticals Announces Third Quarter 2021 Financial Results and Provides Corporate Update
Management to host webcast/conference call today at 2 p.m. PT / 5 p.m. ET SAN DIEGO , Nov. 22, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and